Pharmaceuticals
Takeda's FDA approval of Orzeyful marks a paradigm shift in narcolepsy treatment—the first medicine to directly target orexin deficiency rather than manage symptoms.
Biotechnology
Roche commits $2.3 billion to Hanmi's UCN2 obesity drug candidate, signaling a strategic shift toward muscle-preserving mechanisms beyond GLP-1 agonists.
Pharmaceuticals
The FDA approved a subcutaneous starting dose of lecanemab, allowing Alzheimer's patients to begin treatment at home via weekly self-injection—removing a major access barrier to this disease-modifying therapy.
Biotechnology
The FDA's accelerated approval of Ultragenyx's Genglycos marks the first gene therapy for glycogen storage disease type Ia, signaling a new era in treating rare metabolic diseases at their genetic root.
Wall Street Wire
Moderna's cancer vaccine with Keytruda just worked. That's huge: the stock nearly tripled, and the whole biotech index moved. As attention around oncology innovators increases, several other companies are doing exciting things that may be worth watching.
Biotechnology
Moderna and Merck's personalized mRNA cancer vaccine intismeran autogene has succeeded in its first Phase 3 trial in melanoma, marking the first late-stage win for any mRNA cancer vaccine and raising profound questions about the future of oncology and the mRNA platform itself.
Policy
The FDA's new discussion paper on generative AI-enabled medical devices proposes evaluating AI systems the way physicians are evaluated. The implications for medtech, digital health, and the future of clinical AI are significant.
Biotechnology
AstraZeneca discontinues Phase 3 trial of volrustomig, its PD-1/CTLA-4 bispecific antibody in lung cancer, revealing structural challenges in displacing Keytruda and diverging fortunes in the bispecific antibody race.
Biotechnology
Epicrispr's EPI-321 produced measurable muscle growth in FSHD patients with a single dose, without altering DNA. The $90M Series C and early clinical data mark a potential inflection point for epigenetic medicine.
Get our in depth reports sent directly to your inbox. Unsubscribe anytime.
Definium Therapeutics' Phase 3 Voyage trial shows DT120, a pharmaceutically optimized LSD formulation, achieved an 11.6-point reduction in anxiety scores—the strongest placebo-adjusted efficacy benefit ever observed in a pivotal GAD study.
Eli Lilly filed six lawsuits against black-market sellers of retatrutide on August 12, 2026. The legal action reveals a deeper structural tension in the obesity drug market that litigation alone cannot resolve.
Trump's executive order to reduce childhood vaccines from 17 to 11 raises critical questions about public health policy, pharmaceutical industry impacts, and the politicization of vaccine recommendations.
Silence Therapeutics' Phase 2 SANRECO trial shows divesiran achieved an 88% clinical response rate in polycythemia vera patients, with quarterly dosing that could transform disease management for this rare blood disorder.
Ten of the most followed names in biotech investing funded Entera Bio two weeks ago through its pivotal trial of EB613. Understanding the potential these investors see in Entera requires understanding the Company’s lead asset and how it could transform the way osteoporosis patients are treated.
Senators Pete Ricketts and Elissa Slotkin have introduced the Biotech Investment National Security Act (BINSA), which would subject US-China pharmaceutical deals to federal scrutiny. The bipartisan bill signals a major shift in how Washington views biotech collaboration with China.
Medication errors cost the world an estimated $42 billion a year. Seegnal is tackling the problem with a smarter, patient-specific alert system already used by roughly 15,000 clinicians—and now the company is testing its approach in the U.S.
The FDA's approval of Orzeyful marks the first medicine to treat narcolepsy type 1 by directly restoring orexin signaling, representing a paradigm shift from symptom management to mechanism correction.
LifeMine Therapeutics raised $263 million to develop LIFE-001, a next-generation calcineurin inhibitor designed to prevent organ rejection without the kidney damage caused by current immunosuppressants.
Today is the PDUFA decision date for Moderna's mFlusiva, the first mRNA-based seasonal flu vaccine ever to seek US approval. A unanimous 9-0 advisory panel vote, a 27% efficacy advantage over standard flu shots, and a dramatic regulatory reversal set the stage for a landmark decision.
Novartis receives FDA approval for Pluvicto in metastatic hormone-sensitive prostate cancer, nearly doubling the eligible patient population and validating radioligand therapy's role earlier in the treatment journey.
Novo Nordisk's ZEUS trial failure reveals a critical gap in cardiovascular drug development: reducing inflammation doesn't guarantee clinical benefit. What this means for the future of anti-inflammatory therapies.
